InSite Shares Gain on BromSite Phase III Data

Investors took notice as InSite Vision Inc. reported positive top-line findings from its first Phase III trial of BromSite (ISV-303) for the reduction of inflammation and pain following cataract surgery. The company said BromSite, which combines a low dose (0.075 percent) of the nonsteroidal anti-inflammatory (NSAID) bromfenac with InSite's DuraSite drug delivery technology, achieved statistically significant superiority compared to vehicle.